In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

Clinical Trials Search Results

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 771 for your search:
Cancer Type/Condition:  Non-Hodgkin lymphoma, adult
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 15
Sponsor: Other
Protocol IDs: GMALL05, NCT00199082

2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: Hemato INCAN 01/2007, NCT00429065

3.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HEMOS ALL1105, NCT00797810

4.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3066K1-4438, B1771007, NCT01180049

5.

Phase: Phase IV
Type: Treatment
Status: Active
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: PRT10T, NCT01264822

6.

Phase: Phase IV
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Plerixafor-UF01, NCT01339572

7.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO25455, 2010-023407-95, NCT01461928

8.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011, NCT01501136

9.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011-2, NCT01501149

10.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011-4, NCT01949818

11.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: NILG-ALL 10/07, NCT00795756

12.

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: PRO-1908, PRO1908TREND, NCT01277172

13.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: FIL_VERAL12, NCT01805557

14.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CCBX001-049, NCT00078598

15.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PIX301, NCT00088530

16.

Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000433265, CALGB-50303, ECOG-50303, NCI-05-C-0252, NCT00118209

17.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: DSHNHL 2002-1, NCT00129090

18.

Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: MCL2004-1, NCT00209209

19.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MCL2004-2, NCT00209222

20.

Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930

21.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: HELYX Study, NCT00154440

22.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LMBA02, NCT00180882

23.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: CDR0000459685, DSHNHL-2004-2, EU-205110, EUDRACT-2005-00521738, DSHNHL-FLYER-6664, NCT00278421

24.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: CDR0000459796, DSHNHL-2004-3, EUDRACT-2005-005218-19, EU-205111, NCT00278408

25.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Hx-CD20-405, GENMAB-Hx-CD20-405, OHSU-2634, NCT00394836
1     
New Search